Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era

作     者：Poonam Mathur Shyamasundaran Kottilil Eleanor Wilson 

作者机构：Division of Clinical Care and ResearchInstitute of Human VirologyUniversity of Maryland School of MedicineBaltimoreMDUSA 

出 版 物：《Journal of Clinical and Translational Hepatology》 (临床与转化肝病杂志（英文版）)

年 卷 期：2018年第6卷第4期

页      面：431-437页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：Chronic hepatitis C Direct-acting antivirals Ribavirin 

摘      要：Ribavirin,once a staple of hepatitis C treatment,has significant drawbacks,including treatment-limiting side effects,the requirement for intensive laboratory monitoring,the need for frequent dose adjustments,and *** factors make it difficult to escalate ribavirin-based HCV treatment to most infected patients *** studies have shown comparable response rates between ribavirin-inclusive and ribavirin-sparing regimens in uncomplicated patient ***,ribavirin is still used in the management of patients who have failed previous therapy as well as those with decompensated liver *** this review,we explore the evidence supporting the use of ribavirin in the current climate of hepatitis C treatment with oral combination direct-acting antiviral agents.